Discussion: DMARDs and biologic therapies in the management of inflammatory joint diseases

Expert Review of Clinical Immunology

Volumn 5, Issue 3, 2009, Pages 291-299

  Vaz, Austin ^a   Lisse, Jeffrey ^a   Rizzo, Warren ^b   Albani, Salvatore ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b Advanced Arthritis Care and Research   (United States)

Author keywords

Biologic response modifier; Disease modifying antirheumatic drug; Methotrexate; Rheumatoid arthritis; TNF inhibitor

Indexed keywords

ABATACEPT; ADALIMUMAB; AVARA; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLOSPORIN; DENOSUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; GOLIMUMAB; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 6; JANUS KINASE; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE P38; OCRELIZUMAB; OFATUMUMAB; PROTEIN KINASE SYK; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TETRACYCLINE; TOCILIZUMAB; TRU 015; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTHRITIS; BACTERIAL INFECTION; BIOLOGICAL THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; FEVER; HEADACHE; HEMATOLOGIC DISEASE; HEPATITIS; HEPATITIS B; HUMAN; HYPERTENSION; INFECTIOUS ARTHRITIS; LEUKOPENIA; LIVER TOXICITY; LUPUS LIKE SYNDROME; MALIGNANT NEOPLASTIC DISEASE; MYCOSIS; NAUSEA; NEUROLOGIC DISEASE; PNEUMONIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SKIN INFECTION; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 77649107244     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.14     Document Type: Review

References (49)

1. Da Silva JA, Jacobs JW, Kirwan JR et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann. Rheum. Dis. 65(3), 285-293 (2006
2. Pincus T, Yazici Y, Sokka T et al. Methotrexate as the 'anchor drug' for the treatment of early rheumatoid arthritis. Clin. Exp. Rheumatol. 21(5, Suppl. 31) S179-S185 (2003
3. Cronstein B. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol. Rev. 57, 163-172 (2005
4. Buchbinder R, Barber M, Heuzenroeder L. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Care. Res. 59, 794-799 (2008
5. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363, 675-681 (2004
6. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate vs methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54, 26-37 (2006
7. Smolen JS, van der Heijde DM, St Clair EW et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 54, 702-710 (2006
8. Braun J, Kastner P, Flaxenberg P. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, Phase IV trial. Arthritis Rheum. 58(1), 73-81 (2008
9. Strand V, Cohen S, Schiff M, Weaver A. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch. Intern. Med. 159, 2542-2550 (1999
10. Kremer JM, Genovese MC, Cannon GW et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebocontrolled trial. Ann. Intern. Med. 137, 726-733 (2002
11. Smolen JS, Kalden JR, Scott DL. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353, 259-266 (1999
12. O'Dell JR, Leff R, Paulsen G et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 1164-1170 (2002
13. Makinen H, Kautiainen H, Hannonen P et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J. Rheumatol. 34(2), 316-321 (2007
14. Korpela M, Möttönen T, Laasonen L et al. The impact of initial aggressive drug treatment with DMARDs on the development of joint damage in the long term in patients with rheumatoid arthritis (RA). The 5-year experience from the FIN-RACo study. Arthritis Rheum. 44(9S), S153 (2001
15. Mottonen T, Hannonen P, Leirisalo-Repo M et al. Comparision of combination therapy with single-drug therapy in early rheumatoid arthritis. a randomised trial. FIN-RACo trial group. Lancet 353, 1568-1573 (1999
16. Choy EH, Smith CM, Farrell V et al. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann. Rheum. Dis. 67(5), 656-663 (2008
17. Van der Heijde D, Klareskog L, Rodriguez- Valverde V et al. Comparison of etanercept and methotrexate, alone and in combination, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 54, 1063-1074 (2006
18. Smolen JS, Han C, Bala M et al; ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 52, 1020-1030 (2005
19. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 48(6), 1484-1492 (2003
20. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebocontrolled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54, 2793-2806 (2006
21. Keystone E, Emery P, Peterfy CG et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann. Rheum. Dis. 68(2), 216-221 (2009
22. Keystone E, Fleischmann R, Emery P et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 56(12), 3896-3908 (2007
23. Genovese MC, Becker J-C, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor-necrosis factor ? inhibition. N. Engl. J. Med. 353, 1114-1123 (2005
24. Kremer JM, Genant HK, Moreland LW et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 144(12), 865-876 (2006
25. Gattorno M, Piccini A, Lasigliè D et al. The pattern of response to antiinterleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58, 1505-1515 (2008
26. McGonagle D, Tan AL, Shankaranarayana S, Madden J, Emery P, McDermott MF. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann. Rheum. Dis. 66, 1683-1684 (2007
27. Furst DE, Keystone EC, Kirkham B et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann. Rheum. Dis. 67(Suppl. 3), 2-25 (2008
28. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract. Res. Clin. Rheumatol. 20, 757-790 (2006
29. Keystone E, Heijde D, Mason D Jr et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two week, Phase III, multicenter, randomized, doubleblind placebo-controlled, parallel-group study. Arthritis Rheum. 58(11), 3319-3329 (2008
30. Kay J, Matteson EL, Dasgupta B et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 58(4), 964-975 (2008
31. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371(9617), 987-997 (2008
32. Yokota S, Imagawa T, Mori M et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal Phase III trial. Lancet 371(9617), 998-1006 (2008
33. Genovese MC, Kaine JL, Lowenstein MB et al; ACTION Study Group. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 58(9), 2652-2661 (2008
34. Østergaard M, Baslund B, Rigby W et al. Ofatumumab (HUMAX-CD20), a fully human CD20 monoclonal antibody, in the treatment of rheumatoid arthritis. Early results from an ongoing, double-blind randomized placebo controlled clinical trial (OP0232). Ann. Rheum. Dis. 66(Suppl. 2), 124 (2007
35. Cohen SB, Dore RK, Lane NE et al.; Denosumab Rheumatoid Arthritis Study Group. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, Phase II clinical trial. Arthritis Rheum. 58(5), 1299-1309 (2008
36. Burge DJ, Martin RW, Wallace DJ et al. Repeated therapy with TRU-015 is well tolerated and results in consistent pharmacodymnamic effects in rheumatoid arthritis patients (OP-0252). Ann. Rheum. Dis. 67(Suppl. 2), 128 (2008
37. Williams WV, Scherle P, Shi J et al. Initial efficacy of INCB018424, a selective janus kinase 1 and 2 (Jak 1 and 2) inhibitor in rheumatoid arthritis (OP0044). Ann. Rheum. Dis. 67(Suppl. 2), 62 (2008
38. Damjanov N, Kauffman R, Spencer-Green GT et al. Safety and efficacy of VX-702, a p38 kinase inhibitor, in rheumatoid arthritis (OP0246). Ann. Rheum. Dis. 67 (Suppl. 2), 125 (2008
39. Prakken BJ, Samodal R, Le TD et al. Epitope-specific immunotherapy induces immune deviation of pro-inflammatory T cells in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 101, 4228-4233 (2004
40. Albani S, Prakken B. T cell epitope-specific therapy for rheumatic diseases. Arthritis Rheum. 54, 19-25 (2006
41. Roord S, Zonneeveld-Huijssoon E, Le T et al. Modulation of T cell function by combination of epitope specific and low dose anticytokine therapy controls autoimmune arthritis. PLoS ONE 1, E87 (2006
42. Mäkinen H, Hannonen P, Sokka T. Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission. Clin. Exp. Rheumatol. 24(6, Suppl. 43), S22-S28 (2006
43. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeST study): a randomized, controlled trial. Arthritis Rheum. 52, 3381-3390 (2005
44. Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of TIght COntrol for Rheumatoid Arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364(9430), 263-269 (2004
45. Saag KG, Teng GG, Patakar NM et al. American College of Rheumatology 2008 guidelines for the use of nonbiologic and biologic disease-modifyng antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59(6), 762-784 (2008
46. Verstappen SM, Jacobs JW, van der Veen MJ et al; Utrecht Rheumatoid Arthritis Cohort study group. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann. Rheum. Dis. 66(11), 1443-1449 (2007
47. Etanercept package insert www.enbrel.com/pdf/enbrel-pi.pdf
48. Adalimumab medication guide http://rxabbott.com/pdf/humira-medguide.pdf
49. Infliximab package insert www.remicade.com/pdf/HCP-PPI.pdf